A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

NCT05947812 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID 19 Disease
Mild to Moderate COVID 19 Disease
SARS-CoV-2
Infectious Disease
Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

DRUG: Tafenoquine Oral Tablet
DRUG: Placebo

Sponsor

60P Australia Pty Ltd